Previous 10 | Next 10 |
Gainers: NovaBay Pharmaceuticals (NYSEMKT: NBY ) +34% . Medley Management (NYSE: MDLY ) +33% . Pieris Pharmaceuticals (NASDAQ: PIRS ) +24% . Daxor (NYSEMKT: DXR ) +18% . Oasmia Pharmaceutical AB (NASDAQ: OASM ) +17% . Acasti Pharma (NASDAQ: ACST ) +15% . Mylan N.V. (NASDAQ: MYL...
Smith Micro Software (NASDAQ: SMSI ) +35% on Q2 results . More news on: Smith Micro Software, Inc., Monotype Imaging Holdings Inc., eHealth, Inc., Stocks on the move, Read more ...
Gainers : Therapix Biosciences (NASDAQ: TRPX ) +45% . Chiasma (NASDAQ: CHMA ) +31% . Achillion Pharmaceuticals (NASDAQ: ACHN ) +24% . Hoth Therapeutics (NASDAQ: HOTH ) +20% . Torchlight Energy Resources (NASDAQ: TRCH ) +17% . Realogy Holdings (NYSE: RLGY ) +16% . ClearSign Combustion...
Peak Resorts (NASDAQ: SKIS ) +113% on being acquired by Vail Resorts. More news on: Peak Resorts, Inc., Condor Hospitality Trust, Inc., BioXcel Therapeutics, Inc., Stocks on the move, Read more ...
Innovative XCART technology platform designed to target personalized, patient-specific tumor neoantigens has the potential to transform CAR T cell therapy XCART expected to initially target B-cell lymphomas and has the potential to address multiple tumor types with an initial global m...
Listen on the go! Subscribe now to receive Wall Street Breakfast by 8:00 a.m. every trading day, and by 10:00 a.m. every Saturday, on Seeking Alpha , iTunes , Stitcher and Spotify (click the highlighted links). Stocks faded into the close to finish lower Friday, capping t...
Gainers: Nautilus (NYSE: NLS ) +21% . Francesca's Holdings (NASDAQ: FRAN ) +20% . Anixa Biosciences (NASDAQ: ANIX ) +19% . AVROBIO (NASDAQ: AVRO ) +19% . Rekor Systems (REKR) +18% . Seattle Genetics (NASDAQ: SGEN ) +18% . Hill International (NYSE: HIL ) +18% . scPharmaceutical...
Xenetic Biosciences (NASDAQ: XBIO ) -47% on pricing $15M public offering. More news on: Xenetic Biosciences, Inc., Nu Skin Enterprises, Inc., Immuron Limited, Stocks on the move, Read more ...
FRAMINGHAM, MA / ACCESSWIRE / July 17, 2019 / Xenetic Biosciences, Inc. ( NASDAQ: XBIO) (“Xenetic” or the “Company”), a clinical-stage biopharmaceutical company focused on the discovery, research and development of next-generation biologic ...
Xenetic Biosciences (NASDAQ: XBIO ) has filed another preliminary prospectus , this time for an offering of 1,649,113 common shares, each with an accompanying five-year warrant to purchase one common share at an assumed combined price of $9.02. More news on: Xenetic Biosciences, Inc., Hea...
News, Short Squeeze, Breakout and More Instantly...
Xenetic Biosciences Inc. Company Name:
XBIO Stock Symbol:
NASDAQ Market:
Xenetic Biosciences Inc. Website:
Company's Board of Directors Appoint James F. Parslow to Interim Chief Executive Officer FRAMINGHAM, MA / ACCESSWIRE / May 22, 2024 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immune-oncology technolog...
Ongoing preclinical studies with multiple data readouts expected throughout remainder of 2024 Continued advancement of DNase-based oncology program towards Phase 1 clinical study for the treatment of pancreatic carcinoma and other locally advanced or metastatic solid tumors Ended the qu...
Continued advancement of DNase-based oncology program towards Phase 1 clinical study for the treatment of pancreatic carcinoma and other locally advanced or metastatic solid tumors Ended the year with $9.0 million of cash to fund operations FRAMINGHAM, MA / ACCESSWIRE / March 22, 2024 /...